Lilly’s Diabetes Franchise Poised For A Shakeup As Conterno Steps Down

 
• By Joseph Haas

Lilly’s newer diabetes drugs are selling well, although Trulicity numbers disappointed analysts, and are among the firm’s growth-drivers. Longtime diabetes head Enrique Conterno will be succeeded by insider Mike Mason.

Diabetes - Medical Concept on Grey Background with Blurred Text and Composition of Pills, Syringe and Stethoscope. 3D Render. - Illustration
Diabetes market dynamics took center stage on Lilly's 3Q earnings call

More from Earnings

More from Business